Latest news with #HyBryte
Business Upturn
21-07-2025
- Business
- Business Upturn
Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034)
New York, USA, July 21, 2025 (GLOBE NEWSWIRE) — Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034) | DelveInsight The dynamics of the cutaneous T-cell lymphoma market are anticipated to change owing to the improvement in research and development activities, increasing prevalence, and the rising geriatric population. Additionally, the expected launch of therapies such as HyBryte, PTX-100, Lacutamab, BMS-986369, ONO-4685, and others will also boost the CTCL market growth. DelveInsight's Cutaneous T-cell Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, emerging cutaneous T-cell lymphoma drugs, market share of individual therapies, and current and forecasted cutaneous T-cell lymphoma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Cutaneous T-cell Lymphoma Market Report According to DelveInsight's analysis, the market size for cutaneous T-cell lymphoma was found to be USD 995 million in the 7MM in 2024. in the 7MM in 2024. The United States accounted for the highest cutaneous T-cell lymphoma market size, approximately 70% of the total market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. of the total market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Among the 7MM, the US accounted for the highest number of cases of CTCL in 2024, with nearly 3,000 cases. These cases are anticipated to increase by 2034. cases. These cases are anticipated to increase by 2034. Prominent cutaneous T-cell lymphoma companies, including Soligenix and Sterling Pharma Solutions, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, ONO Pharmaceutical, and others, are actively working on innovative cutaneous T-cell lymphoma drugs. and others, are actively working on innovative cutaneous T-cell lymphoma drugs. Some of the key cutaneous T-cell lymphoma therapies in the pipeline include HyBryte (Synthetic Hypericin/SGX301), PTX-100, Lacutamab (IPH4102), BMS-986369 (Golcadomide), ONO-4685 , and others. These novel cutaneous T-cell lymphoma therapies are anticipated to enter the cutaneous T-cell lymphoma market in the forecast period and are expected to change the market. , and others. These novel cutaneous T-cell lymphoma therapies are anticipated to enter the cutaneous T-cell lymphoma market in the forecast period and are expected to change the market. By 2034, among all the therapies in the late stage, the highest revenue is expected to be generated by POTELIGEO in the 7MM. in the 7MM. In May 2025, 4SC received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorization Application (MAA) for KINSELBY, intended for the treatment of advanced-stage CTCL, leading to the decision to discontinue its further development and commercialization. received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing Authorization Application (MAA) for KINSELBY, intended for the treatment of advanced-stage CTCL, leading to the decision to discontinue its further development and commercialization. In March 2025, Prescient Therapeutics opened the first clinical site for its Phase IIa study of PTX-100 in patients with relapsed or refractory CTCL. opened the first clinical site for its Phase IIa study of PTX-100 in patients with relapsed or refractory CTCL. In February 2025, Citius Pharmaceuticals and its oncology-focused subsidiary, Citius Oncology, announced that LYMPHIR has been assigned a unique, permanent HCPCS J-code (J9161) by the CMS. The establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR, providing coding clarity for physicians and facilities who administer LYMPHIR, and facilitating reimbursement. Discover which cutaneous T-cell lymphoma medications are expected to grab the market share @ Cutaneous T-cell Lymphoma Market Report Cutaneous T-cell Lymphoma Overview Cutaneous T-cell lymphoma (CTCL) is a form of non-Hodgkin lymphoma that begins in the skin, arising from T lymphocytes—a type of white blood cell that plays a key role in immune defense against infections and cancer. Unlike other lymphomas that typically originate in the lymph nodes or internal organs, CTCL starts in the skin, which itself functions as a major lymphoid organ. Although B-cell lymphomas are generally more common, T-cell lymphomas like CTCL are more frequently found in the skin. Diagnosing CTCL involves a comprehensive clinical evaluation, including a review of symptoms, physical examination, detailed medical history, and specialized diagnostic tests. These tests help identify the exact type and stage of the disease and guide treatment planning. Skin biopsies are a standard diagnostic tool, particularly because early CTCL can mimic benign skin disorders such as psoriasis. In many cases, multiple biopsies are needed to establish a definitive diagnosis due to the subtle and variable nature of early-stage CTCL. Cutaneous T-cell Lymphoma Epidemiology Segmentation The cutaneous T-cell lymphoma epidemiology section provides insights into the historical and current cutaneous T-cell lymphoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The cutaneous T-cell lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Incident Cases of CTCL Type-specific Cases of CTCL Gender-specific Cases of CTCL Stage-specific Cases of CTCL Treatment-eligible Pool in Early and Advanced Stages of CTCL Download the report to understand which factors are driving cutaneous T-cell lymphoma epidemiology trends @ Cutaneous T-cell Lymphoma Treatment Algorithm Cutaneous T-cell Lymphoma Treatment Market The treatment strategy for mycosis fungoides and Sézary syndrome, both forms of cutaneous T-cell lymphoma, varies depending on the extent of skin involvement and whether the disease has spread. Mycosis fungoides typically responds well to therapies directed at the skin or the whole body, whereas Sézary syndrome usually necessitates systemic treatment approaches. VALCHLOR (mechlorethamine) is the first and only FDA-approved topical formulation of mechlorethamine for patients with Stage IA or IB mycosis fungoides-type CTCL who have previously undergone skin-directed therapy. For patients with early-stage disease, topical corticosteroids are considered the first-line treatment. Additionally, topical Toll-like Receptor (TLR) agonists, which stimulate local production of interferons and cytokines to promote tumor cell death and enhance the immune response, have shown clinical benefit in managing limited-stage mycosis fungoides. In cases of advanced-stage mycosis fungoides or Sézary syndrome, a comprehensive and multidisciplinary approach is required. Management often involves combinations of skin-directed therapies, immune-modulating agents, and sequential systemic chemotherapy. However, for early-stage disease, multi-agent chemotherapy is generally avoided. Instead, a risk- and stage-adapted strategy, aligned with the National Comprehensive Cancer Network (NCCN) Guidelines, is typically used. This includes the use of biologic-response modifiers (such as bexarotene and interferon-alpha), histone deacetylase (HDAC) inhibitors (like romidepsin), or targeted therapies such as monoclonal antibodies or antibody-drug conjugates (e.g., mogamulizumab, brentuximab vedotin). Treatment choices are tailored to each patient, taking into account factors such as age, overall health, disease stage and burden, progression rate, and prior treatments. For advanced-stage CTCL (Stages IIB–IV), effective systemic therapies include HDAC inhibitors such as ISTODAX (romidepsin) and ZOLINZA (vorinostat). Notably, vorinostat was the first HDAC inhibitor to gain FDA approval in 2006 for treating progressive, persistent, or relapsing CTCL. Learn more about the cutaneous T-cell lymphoma treatment options @ Cutaneous T-cell Lymphoma Treatment Guidelines Cutaneous T-cell Lymphoma Emerging Drugs and Companies Some of the drugs in the pipeline include HyBryte (Soligenix and Sterling Pharma Solutions), PTX-100 (Prescient Therapeutics), Lacutamab (Innate Pharma), Golcadomide (Bristol Myers Squibb), and others. HyBryte is a topical formulation containing hypericin, one of the most light-sensitive compounds known. The product has been granted both Orphan Drug Designation and Fast Track Designation by the U.S. FDA, along with orphan status from the European Medicines Agency (EMA). Soligenix showcased new clinical data supporting HyBryte's use in treating cutaneous T-cell lymphoma at two major events: the United States Cutaneous Lymphoma Consortium (USCLC) Workshop on March 6, 2025, and the American Academy of Dermatology (AAD) Annual Meeting held from March 7 to 11, 2025. In an April 2024 press release, the company stated it expects to report top-line results from its 18-week confirmatory FLASH2 study, being conducted in both the U.S. and Europe, during the second half of 2026. PTX-100 is a novel, first-in-class agent that inhibits a key enzyme involved in cancer progression by targeting the oncogenic Ras signaling pathway. The drug is currently undergoing a Phase IIa trial in patients with relapsed or refractory CTCL, with potential progression to a Phase IIb registration study. As outlined in Prescient Therapeutics' May 2025 investor update, the company expects to receive Orphan Drug Designation in Europe by Q3 2025. Additionally, an interim review of Phase IIa trial data is planned for Q4 2025 or early 2026. Prescient also announced in May 2025 that the first patient had been successfully dosed in this ongoing Phase IIa study. Lacutamab is a humanized, first-in-class antibody targeting KIR3DL2, designed to induce cytotoxicity. It is being tested in an open-label, multicohort Phase II study in CTCL and another Phase II study in peripheral T-cell lymphoma (PTCL). According to Innate Pharma's most recent annual update from May 2025, the company aims to begin a Phase III trial of lacutamab, with plans to pursue accelerated approval by 2027. Furthermore, long-term follow-up data from the TELLOMAK Phase II trial, focusing on patients with Sézary syndrome and mycosis fungoides, will be presented at the 2025 ASCO Annual Meeting on June 2 in Chicago, Illinois. The anticipated launch of these emerging cutaneous T-cell lymphoma therapies are poised to transform the cutaneous T-cell lymphoma market landscape in the coming years. As these cutting-edge cutaneous T-cell lymphoma therapies continue to mature and gain regulatory approval, they are expected to reshape the cutaneous T-cell lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about new treatment for cutaneous T-cell lymphoma, visit @ Cutaneous T-cell Lymphoma Management Cutaneous T-cell Lymphoma Market Dynamics The cutaneous T-cell lymphoma market dynamics are anticipated to change in the coming years. The prognosis for most patients with CTCL is promising, especially with early detection and timely treatment, which can enable decades of survival with ongoing care. However, the disease's heterogeneity and involvement of multiple pathways create a strong foundation for the development of diverse targeted therapies. Emerging evidence supporting PTX-100's superior efficacy and safety over LYMPHIR further underscores the potential of targeting GGT1 inhibition. Combined with the limited pipeline activity in CTCL, this presents a significant opportunity for drug developers to innovate and bring novel therapies to an underserved market. Furthermore, many potential therapies are being investigated for the treatment of cutaneous T-cell lymphoma, and it is safe to predict that the treatment space will significantly impact the cutaneous T-cell lymphoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the cutaneous T-cell lymphoma market in the 7MM. However, several factors may impede the growth of the cutaneous T-cell lymphoma market. The diagnosis and treatment of cutaneous T-cell lymphoma remain challenging due to several factors: multiple biopsies are often required for a definitive diagnosis, potentially delaying appropriate treatment; the underlying mechanisms driving CTCL-associated pruritus are still poorly understood despite advances in research; targeted therapies frequently face issues of limited tolerance and efficacy, leading to discontinuation from toxicity or resistance; and the recent negative opinion and discontinuation of KINSELBY underscore regulatory risks, casting uncertainty over the future development of similar therapies. Moreover, cutaneous T-cell lymphoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the cutaneous T-cell lymphoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the cutaneous T-cell lymphoma market growth. Cutaneous T-cell Lymphoma Report Metrics Details Study Period 2020–2034 Cutaneous T-cell Lymphoma Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Cutaneous T-cell Lymphoma Market CAGR 7.1% Cutaneous T-cell Lymphoma Market Size in 2024 USD 995 Million Key Cutaneous T-cell Lymphoma Companies Soligenix and Sterling Pharma Solutions, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, ONO Pharmaceutical, Kyowa Hakko Kirin, Pfizer (Seagen), Takeda, Helsinn Therapeutics, Citius Pharmaceuticals, Valeant Pharmaceuticals, Bausch Health, and others Key Cutaneous T-cell Lymphoma Therapies HyBryte (Synthetic Hypericin/SGX301), PTX-100, Lacutamab (IPH4102), BMS-986369 (Golcadomide), ONO-4685, POTELIGEO, ADCETRIS, VALCHLOR/LEDAGA, LYMPHIR, TARGRETIN, ISTODAX, and others Scope of the Cutaneous T-cell Lymphoma Market Report Cutaneous T-cell Lymphoma Therapeutic Assessment: Cutaneous T-cell Lymphoma current marketed and emerging therapies Cutaneous T-cell Lymphoma current marketed and emerging therapies Cutaneous T-cell Lymphoma Market Dynamics: Conjoint Analysis of Emerging Cutaneous T-cell Lymphoma Drugs Conjoint Analysis of Emerging Cutaneous T-cell Lymphoma Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cutaneous T-cell Lymphoma Market Access and Reimbursement Discover more about cutaneous T-cell lymphoma drugs in development @ Cutaneous T-cell Lymphoma Clinical Trials Table of Contents 1 Key Insights 2 CTCL Market Report Introduction 3 Executive Summary 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 CTCL Market Overview at a Glance 7 Disease Background and Overview 8 CTCL Treatment 8.1 Treatment of Limited-stage Mycosis Fungoides/Sézary Syndrome 8.2 Treatment of Advanced-stage Mycosis Fungoides/Sezary Syndrome 8.3 CTCL Treatment Guidelines 9 Epidemiology and Patient Population 9.1 Key Findings 9.2 Assumptions and Rationale 9.3 Total Incident Cases of CTCL in the 7MM 9.4 The United States 9.5 EU4 and the UK 9.6 Japan 10 Patient Journey 11 CTCL Marketed Drugs 11.1 Key Competitors 11.2 POTELIGEO (mogamulizumab): Kyowa Hakko Kirin 11.2.1 Product Description 11.2.2 Regulatory Milestones 11.2.3 Other Developmental Activities 11.2.4 Clinical Development 11.2.4.1 Clinical Trial Information 11.2.5 Safety and Efficacy 11.2.6 Analyst Views 11.3 ADCETRIS (brentuximab vedotin): Pfizer (Seagen) and Takeda 11.4 VALCHLOR/LEDAGA (mechlorethamine): Helsinn Therapeutics 11.5 LYMPHIR/REMITORO/E7777/ONTAK (denileukin diftitox): Citius Pharmaceuticals 12 Discontinued Therapy 12.1 KINSELBY (resminostat): 4SC 12.1.1 Product Description 12.1.2 Other Developmental Activities 12.1.3 Clinical Development 12.1.3.1 Clinical Trials Information 12.1.4 Safety and Efficacy 12.1.5 Analyst Views 13 CTCL Emerging Therapies 13.1 Key Cross Competition 13.2 HyBryte (Synthetic Hypericin/SGX301): Soligenix and Sterling Pharma Solutions 13.2.1 Product Description 13.2.2 Other Developmental Activities 13.2.3 Clinical Development 13.2.3.1 Clinical Trials Information 13.2.4 Safety and Efficacy 13.2.5 Analyst Views 13.3 PTX-100: Prescient Therapeutics 13.4 Lacutamab (IPH4102): Innate Pharma 14 CTCL: Seven Major Market Analysis 14.1 Key Findings 14.2 Market Outlook 14.3 Conjoint Analysis 14.4 Key Market Forecast Assumptions 14.4.1 Cost Assumptions and Rebate 14.4.2 Pricing Trends 14.4.3 Analogue Assessment 14.4.4 Launch Year and Therapy Uptake 14.5 Total Market Size of CTCL in the 7MM 14.6 The United States Market Size 14.7 EU4 and the UK Market Size 14.8 Japan 15 Unmet Needs 16 SWOT Analysis 17 KOL Views 18 CTCL Market Access and Reimbursement 18.1 United States 18.2 EU4 and the UK 18.3 Japan 18.4 Market Access and Reimbursement of CTCL 19 Bibliography 20 Report Methodology Related Reports Cutaneous T-cell Lymphoma Pipeline Cutaneous T-cell Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CTCL companies, including Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc., among others. Non-Hodgkin's Lymphoma Market Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others. Non-Hodgkin's Lymphoma Pipeline Non-Hodgkin's Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., among others. Peripheral T-Cell Lymphoma Market Peripheral T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PTCL companies, including Secura Bio, Shanghai YingLi Pharmaceutical, Dizal Pharmaceuticals, Viracta Therapeutics, Innate Pharma, CStone Pharmaceuticals, Affimed, Otsuka Pharmaceutical, Astex Pharmaceuticals, Autolus, Myeloid Therapeutics, Merck Sharp & Dohme, Bristol Myers Squibb, among others. Diffuse Large B-cell Lymphoma Market Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DLBCL companies, including Roche (Genentech), Biogen, Nektar Therapeutics, Merck, Allogene Therapeutics, Miltenyi Biomedicine, AstraZeneca, BioVaxys, ImmunoVaccine Technologies, Cellectar Biosciences, Galapagos, Novartis, Lyell, ImmPACT Bio, Pfizer, Kartos Therapeutics, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Ranok Therapeutics, Constellation Pharmaceuticals, Genmab, IDP Discovery Pharma S.L., Immunitas Therapeutics, Monte Rosa Therapeutics, SymBio Pharmaceuticals, AVM Biotechnology, Autolus Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Caribou Biosciences, Adicet Bio, Gilead Sciences, Xynomic Pharmaceuticals, Amgen, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Globe and Mail
03-07-2025
- Business
- Globe and Mail
Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Mycosis Fungoides Pipeline Insight, 2025 ' report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Mycosis Fungoides pipeline landscape. It covers the Mycosis Fungoides pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mycosis Fungoides pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Mycosis Fungoides Pipeline. Dive into DelveInsight's comprehensive report today! @ Mycosis Fungoides Pipeline Outlook Key Takeaways from the Mycosis Fungoides Pipeline Report In June 2025, M.D. Anderson Cancer Center announced a study of ultra-low-dose-total-skin electron beam therapy with brentuximab vedotin (ULD-TSEBT+BV) among patients with stage I-IV mycosis fungoides/Sezary syndrome. In June 2025, Soligenix conducted a Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. All of the participant's lesions that are readily available for exposure to the visible light source will be treated and 3 to 5 index lesions in each patient will be prospectively identified and documented for modified Composite Assessment of Index Lesion Severity (mCAILS) evaluation. Participants will be followed every 4 weeks for a total of 12 weeks following their last light session. DelveInsight's Mycosis Fungoides Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Mycosis Fungoides treatment. The leading Mycosis Fungoides Companies such as Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Promising Mycosis Fungoides Pipeline Therapies such as Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Stay ahead with the most recent pipeline outlook for Mycosis Fungoides. Get insights into clinical trials, emerging therapies, and leading companies with Mycosis Fungoides @ Mycosis Fungoides Treatment Drugs Mycosis Fungoides Emerging Drugs Profile Hypericin: Soligenix HyBryte™ (research name SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by safe, visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. Currently, the drug is in Phase III stage of its development for the treatment of Mycosis Fungoides. IPH4102: Innate Pharma Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Lacutamab has been granted U.S. FDA Breakthrough Therapy Designation for relapsed or refractory Sézary syndrome. Innate Pharma SA announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory (r/r) Sézary syndrome (SS) after at least 2 prior systemic therapies including mogamulizumab. Currently, the drug is in Phase II stage of its development for the treatment of Mycosis Fungoides. The Mycosis Fungoides Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Mycosis Fungoides with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mycosis Fungoides Treatment. Mycosis Fungoides Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Mycosis Fungoides Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mycosis Fungoides market Explore groundbreaking therapies and clinical trials in the Mycosis Fungoides Pipeline. Access DelveInsight's detailed report now! @ New Mycosis Fungoides Drugs Mycosis Fungoides Companies Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Mycosis Fungoides Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Mycosis Fungoides Treatment. Learn about new drugs, Mycosis Fungoides Pipeline developments, and key companies with DelveInsight's expert analysis @ Mycosis Fungoides Market Drivers and Barriers Scope of the Mycosis Fungoides Pipeline Report Coverage- Global Mycosis Fungoides Companies- Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides Pipeline Therapies- Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Mycosis Fungoides Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Mycosis Fungoides Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Mycosis Fungoides Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Mycosis Fungoides Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Mycosis Fungoides: Overview Pipeline Therapeutics Therapeutic Assessment Mycosis Fungoides– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Hypericin: Soligenix Drug profiles in the detailed report….. Mid Stage Products (Phase II) IPH4102: Innate Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Mycosis Fungoides Key Companies Mycosis Fungoides Key Products Mycosis Fungoides- Unmet Needs Mycosis Fungoides- Market Drivers and Barriers Mycosis Fungoides- Future Perspectives and Conclusion Mycosis Fungoides Analyst Views Mycosis Fungoides Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
